Establishment of personalized treatment for BIM deletion polymorphism-positive lung cancer using circulating tumor cells
Project/Area Number |
18K08189
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 53030:Respiratory medicine-related
|
Research Institution | Toho University |
Principal Investigator |
|
Project Period (FY) |
2018-04-01 – 2021-03-31
|
Project Status |
Completed (Fiscal Year 2020)
|
Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
Keywords | EGFR遺伝子変異陽性非小細胞肺癌 / オシメルチニブ / BIM-γ / 循環腫瘍細胞 / EGFR遺伝子変異 / BIM / BIM遺伝子多型 / 耐性遺伝子 / 原発性肺癌 / 非小細胞肺癌 |
Outline of Final Research Achievements |
A prospective study was conducted to clarify the relationship between the response rate of osimertinib in EGFR mutation-positive non-small cell lung cancer and the mRNA expression level of BIM-γ in circulating tumor cells. Circulating tumor cells were harvested using the ClearCell FX system and subjected to quantitative real-time PCR. The response rate of osimertinib was lower in the BIM-γ high expression group (n = 15) than in the BIM-γ low expression group (n = 15) (26% vs. 73.3%, p = 0.011). It was suggested that overexpression of BIM-γ mRNA in circulating tumor cells of patients with EGFR mutation-positive non-small cell lung cancer could be a poor prognostic factor for osimertinib.
|
Academic Significance and Societal Importance of the Research Achievements |
本研究は血液検体を用いた確実なサンプリングに基づいた個別化治療のシステム構築を目的にしており、得られた結果はBIM-γのmRNAの発現量を層別化因子とした原発性肺癌の個別化治療法の確立に大きく貢献するもので、本研究は非常に特色のある研究であると同時にその社会的意義も大きい。
|
Report
(4 results)
Research Products
(12 results)
-
[Journal Article] Quantification of BIM mRNA in circulating tumor cells of osimertinib-treated patients with EGFR mutation-positive lung cancer.2021
Author(s)
Isobe K, Yoshizawa T, Sekiya M, Miyoshi S, Nakamura Y, Urabe N, Isshiki T, Sakamoto S, Takai Y, Tomida T, Adachi-Akahane S, Iyoda A, Homma S, Kishi K.
-
Journal Title
Respir Investig
Volume: in press
Issue: 4
Pages: 535-544
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Clinical importance of long non coding RNA LINC00460 expression in EGFR mutant lung adenocarcinoma.2020
Author(s)
Nakano Y, Isobe K, Kobayashi H, Kaburaki K, Isshiki T, Sakamoto S, Takai Y, Tochigi N, Mikami T, Iyoda A, Homma S, Kishi K.
-
Journal Title
Int J Oncol.
Volume: 56
Pages: 243-257
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
[Presentation] Quantification of PD-L1 mRNA Expression in EGFR-mutant Lung Adenocarcinoma2018
Author(s)
Isobe K, Kakimoto A, Kaburaki K, Kobayashi H, Sano G, Sakamoto S, Takai Y, Tochigi N, Mikami T, Iyoda A, Homma H
Organizer
European Society for Medical Oncology (ESMO) 2018 Congress
Related Report
Int'l Joint Research
-
[Presentation] Survival Effect of Long Intergenic Non-Protein Coding RNA 460 Expression in EGFR-Mutant Adenocarcinoma.2018
Author(s)
Nakano Y, Isobe K, Kakimoto A, Kobayashi H, Kaburaki K, Sano G, Sakamoto S, Takai Y, Tochigi N, Mikami T, Iyoda A, Homma S
Organizer
European Society for Medical Oncology (ESMO) 2018 Congress
Related Report
Int'l Joint Research
-
-
-